[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuroendocrine-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuroendocrine-neoplasm":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,63,104,131,160,184,211,237,260,285,310,356,380],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100602879","phase-1-a-study-to-investigate-safety-and-effectiveness-of-crn09682-in-participants-with-sst2-expressing-nens-and-other-solid-tumors-100602879",false,"NCT07129252","A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","A Phase 1\u002F2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors","BRAVESST2","Inclusion Criteria:\n\n* Have a histological diagnosis of metastatic or locally advanced inoperable NET, NEC, or other solid tumors that have confirmed radiological progression.\n* Have one or more measurable disease location per RECIST version 1.1.\n* Have a tumor that expresses SSR confirmed by SSR imaging.\n* Have an ECOG performance status of 0, 1, or 2.\n\nExclusion Criteria:\n\n* Have tumor progression while undergoing a course of PRRT or within 6 months of completing PRRT.\n* Have brain metastases unless asymptomatic and stable for at least one month for participants with SCLC or LCLC or at least 3 months for participants with other non-NET solid tumors.\n* Use of anticancer agents within specified intervals prior to the first dose of study drug.\n* Had surgery, chemoembolization, or radiofrequency ablation within 90 days prior to first dose of study drug.\n* Prior participation in any intervention clinical study within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.\n* Participants with carcinoid syndrome.\n* Secondary malignancy: participants who have any other malignancy known to be active or treated within 3 years of the start of screening, with the exception of treated cervical intraepithelial neoplasia, superficial (noninvasive) bladder cancer, and non-melanoma skin cancer.\n* Have prior treatment with MMAE.\n* Have hypersensitivity or history of anaphylactic reaction to octreotide, other SSAs, and\u002For MMAE.","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This Phase 1\u002F2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.",[28,29,30],"SST2-positive Neuroendocrine Neoplasms","Neuroendocrine Tumors","Neuroendocrine Neoplasm",[32,33,30,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49],"CRN09682","Crinetics","NEN","Neuroendocrine Tumor","NET","MMAE","SST2","Somatostatin","Metastatic","Solid Tumor","Dose Escalation","Dose Expansion","Phase 1","SSTR+","Phase 2","Phase 1\u002F2","Neuroendocrine Carcinoma","NEC","RECRUITING","2026-06-30",{"date":53,"type":54},"2026-07-01","ACTUAL",{"date":56,"type":54},"2025-11-26",{"date":58,"type":21},"2029-08",{"name":60,"class":61},"Crinetics Pharmaceuticals Inc.","INDUSTRY",26,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100239986","project-every-child-for-younger-patients-with-cancer-100239986","NCT02402244","Project: Every Child for Younger Patients With Cancer","The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study","Inclusion Criteria:\n\n* Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem\n* Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority\n* Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:\n\n  * All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one \"1\" (borderline), two \"2\" (carcinoma in situ) or three \"3\" (malignant)\n  * All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant\n  * All neoplastic lesions of the kidney regardless of behavior, i.e., benign, borderline or malignant\n  * The following other benign\u002Fborderline conditions:\n\n    * Mesoblastic nephroma\n    * Teratomas (mature and immature types)\n    * Myeloproliferative diseases including transient myeloproliferative disease\n    * Langerhans cell histiocytosis\n    * Lymphoproliferative diseases\n    * Desmoid tumors\n    * Gonadal stromal cell tumors\n    * Neuroendocrine tumors including pheochromocytoma\n    * Melanocytic tumors, except clearly benign nevi\n    * Ganglioneuromas\n* Subjects must be =\\\u003C 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network \\[NCTN\\]) therapeutic study, for which there is a higher upper age limit\n* All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission\n\n  * If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1","25 Years",{"count":72,"type":21},75000,"OBSERVATIONAL","This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.",[76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,30,92],"Adrenal Gland Pheochromocytoma","Carcinoma In Situ","Central Nervous System Neoplasm","Childhood Immature Teratoma","Childhood Kidney Neoplasm","Childhood Langerhans Cell Histiocytosis","Childhood Mature Teratoma","Congenital Mesoblastic Nephroma","Desmoid Fibromatosis","Ganglioneuroma","Lymphoproliferative Disorder","Malignant Neoplasm","Malignant Solid Neoplasm","Melanocytic Neoplasm","Myeloproliferative Neoplasm","Neoplasm of Uncertain Malignant Potential","Stromal Neoplasm","2026-05-01",{"date":95,"type":54},"2026-05-05",{"date":97,"type":54},"2015-11-03",{"date":99,"type":21},"2030-12-31",{"name":101,"class":102},"Children's Oncology Group","NETWORK",278,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":130},"100572379","phase-1-a-phase-i-study-to-assess-the-safety-and-efficacy-of-225acac-dotatate-in-patients-with-sstr-gep-nens-100572379","NCT06732505","A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens","A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With Inoperable, Locally Advanced or Metastatic, Progressive, Well-Differentiated,SSTR+ GEP-Nens","Inclusion Criteria:\n\n1. Patients must have the ability to understand and sign an approved informed consent form (ICF).\n2. Patients must be \\>= 18 and \\\u003C＝80 years of age.\n3. Histopathologically confirmed G1 or G2 or G3 GEP-NET or GEP-NEC；\n4. Unresectable locally advanced or metastatic GEP-NET which confirmed by imaging examination.\n5. G1 or G2 NET patients: previously received fixed-dose Octreotide LAR (20-30 mg\u002F3-4 weeks) for at least 12 weeks of continuous treatment with disease progression;G3 NET orNEC patients: previously received at least 1 line therapy with disease progression.\n6. Presence of at least 1 measurable site of disease (based on RECIST 1.1).\n7. SSTR-PET positive.\n8. ECOG score of 0 or 1.\n9. Life expectancy of at least 12 weeks.\n10. Sufficient bone marrow capacity and organ function:\n\n    Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 ml\u002Fmin (Cockcroft Gault formula).\n\n    Hemoglobin≥90g\u002FL, neutrophil count ≥1.5×10\\^9\u002FL, platelets≥100×10\\^9\u002FL. Serum total bilirubin ≤1.5×ULN. Serum albumin ≥30g\u002FL. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5×ULN，or ALT\u002FAST≤5×ULN with liver metastases.\n\n    Partially activated prothrombin time (APTT) ≤1.5 x ULN.\n11. Subjects of childbearing potential voluntarily use an effective method of contraception, such as condoms, oral or injectable contraceptives, IUDs, etc., during treatment and within 6 months of the last use of the trial drug.\n\nExclusion Criteria:\n\n1. Pregnant or lactating females.\n2. Received the following treatments within 4 weeks prior to initiation of study treatment, including but not limited to surgery (except biopsy), radical radiotherapy, hepatic artery interventional embolization, cryoablation of liver metastases, or radiofrequency ablation.\n3. Received systemic antitumor therapy such as targeted therapy, immunotherapy, antitumor herbal therapy, chemotherapy within 4 weeks prior to initiation of study treatment.\n4. Rapid progression with previous PRRT therapy.\n5. Any patient receiving treatment with short-acting Octreotide, which cannot be interrupted for 24 h before and 24 h after the administration of initiation of study treatment, or any patient receiving treatment with Octreotide LAR, which cannot be interrupted for at least 6 weeks before the administration of initiation of study treatment.\n6. Toxicity of prior antitumor therapy has not returned to ≤ grade 1 levels (except for alopecia).\n7. Received external beam radiation therapy for bone metastases within 2 weeks prior to initiation of study treatment.\n8. Known brain metastases, unless these metastases have been treated and stabilized for at least 24 weeks, prior to enrollment in the study.\n9. Uncontrolled congestive heart failure.\n10. uncontrolled diabetes mellitus, including baseline fasting glucose \\> 2 x ULN.\n11. Known other malignancies (except for those without recurrence within 5 years after adequate treatment).\n12. Known hypersensitivity to Lutetium\\[177Lu\\] Oxodotreotide Injection or \\[225Ac\\]Ac-DOTATATE Injection and their excipients.\n13. Known to be unsuitable for enhanced CT or MRI contrast imaging due to allergic reaction or renal insufficiency.\n14. Any clinically significant active infection.\n15. Participated in other drug clinical trials within 4 weeks prior to initiation of study treatment and received treatment with the corresponding trial drug.\n16. Any other disease, mental status or surgical condition that is uncontrolled, may interfere with study completion (including poor compliance) or is inappropriate for the use of the investigational drug.\n17. Other treatment options (e.g., chemotherapy, targeted therapy) that, in the opinion of the investigator, are more appropriate for the patient than the treatment provided in the study based on the patient's disease characteristics.\n18. Unsuitable for the study for any reason, in the opinion of the investigator.","80 Years",{"count":113,"type":21},36,[24],"This is a phase I study to assess the safety and efficacy of \\[225Ac\\]Ac-DOTATATE in patients with inoperable, locally advanced or metastatic, progressive, Well-Differentiatedwell differentiated, somatostatin receptor positive gastroenteropancreatic neuroendocrine neoplasms with either no prior history of peptide receptor radionuclide therapy (PRRT naive) or prior history of peptide receptor radionuclide therapy (Previous PRRT).",[30],[118,119],"[225Ac]Ac-DOTATATE","neuroendocrine neoplasm","2025-06-22",{"date":122,"type":54},"2025-06-26",{"date":124,"type":54},"2024-09-29",{"date":126,"type":21},"2026-03-31",{"name":128,"class":129},"Peking University Cancer Hospital & Institute","OTHER",1,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":139,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":130},"100398130","rediscovering-biomarkers-for-the-diagnosis-and-early-treatment-response-in-nen-reborn-100398130","NCT04464122","Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN. REBORN Study","REBORN","Inclusion Criteria:\n\n* Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group);\n* Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (control group).\n\nExclusion Criteria:\n\n* Severe chronic kidney disease (stage 4-5);\n* Clinical or laboratory signs of significant respiratory, cardiological and hepatobiliary disease;\n* Other non-neuroendocrine malignancies.",{"count":140,"type":21},60,"This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.",[29,30,143,144,48],"Neuroendocrine Tumor Grade 1","Neuroendocrine Tumor Grade 2",[146,147,148,149,150],"Neuroendocrine Tumours","Prognostic markers","Tumour educated platelets","angiogenesis","immune function","2025-03-31",{"date":153,"type":54},"2025-04-03",{"date":155,"type":54},"2020-09-14",{"date":157,"type":21},"2025-12-31",{"name":159,"class":129},"University of Roma La Sapienza",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100451969","phase-2-sintilimab-combined-with-ibi310-and-surufatinib-for-the-treatment-of-g3-net-and-nec-nessie-100451969","NCT05165407","Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)","Sintilimab Combined With IBI310 and Surufatinib for the Treatment of High-grade Advanced-neuroendocrine Neoplasms: a Single Arm, Open-label, Multi Center, Phase II Study","NESSIE","Inclusion Criteria:\n\n* Patients who included in this study must fulfil all of the following criteria:\n\n  1. Fully aware of this study and voluntary to sign the informed consent form (the informed consent form must be signed before any trial-specific procedure is performed);\n  2. Aged 18-75 (inclusive);\n  3. Histologically or cytologically confirmed patients with inoperable or metastatic high-grade neuroendocrine neoplasm (Ki67 index \\> 20% or with mitotic count of more than 20 mitoses per high power field);\n  4. Patients who failed to receive standard treatment (Have progressed on previous treatment, or treatment toxicity and side effects are not tolerated), or cannot receive standard treatment (including patients who are intolerant to standard treatment, who are judged by the investigator to be unsuitable for standard treatment or who refuse to receive standard treatment), or who have no standard treatment plan;\n  5. Having clear measurable lesions (according to RECIST 1.1). If the lesion is the only one that has received previous local treatment (radiotherapy, ablation, vascular intervention, etc.), there must be clear imaging evidence of disease progression in that lesion;\n  6. Agree to provide tumor specimens (for further diagnosis of pathological grade, detection of PD-L1 expression and lymphocyte infiltration);\n  7. ECOG performance status of 0 or 1;\n  8. Brain metastases are asymptomatic or stable after local treatment are allowed to be enrolled as long as they meet the following conditions:\n\n  1\\) Measurable lesions are outside of the central nervous system 2) No central nervous system symptoms or no exacerbation of symptoms for at least 2 weeks 3) No glucocorticoid treatment or discontinuation of glucocorticoid treatment within 7 days before first dose of study treatment.\n\n  9\\. Patients were allowed to receive palliative radiation therapy, but it ended 14 days before the first dose of study treatment, and the radiation-related toxicity returned to grade 1 or less (CTCAE5.0); 10. Predicted survival ≥ 3 months; 11. Patients with adequate organ functions whose laboratory tests within 7 days before the first dose meet the following requirements:\n  1. Absolute neutrophil count (ANC) ≥1.5x109\u002FL within 14 days, without use of granulocyte colony-stimulating factor or other hematopoietic stimulating factor.\n  2. Platelet count ≥100×109\u002FL within 14 days, without blood transfusion or use of blood product.\n  3. Hemoglobin ≥ 9 g\u002FdL within 14 days, without blood transfusion or erythropoietin.\n  4. Total bilirubin ≤1.5 × upper limit of normal (ULN); Such as total bilirubin \\> 1.5×ULN, but direct bilirubin ≤ ULN was also allowed.\n  5. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤2.5×ULN (ALT or AST ≤5×ULN in patients with liver metastasis).\n  6. Serum creatinine ≤1.5×ULN and creatinine clearance rate ≥60 mL \u002Fmin (calculated according to the Cockcroft-Gault formula).\n  7. Good coagulation function, defined as International normalized ratio (INR) or prothrombin time (PT) ≤1.5 ULN;\n  8. Normal thyroid function, defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can be enrolled; Hypothyroidism that can be controlled only by thyroid hormone replacement therapy can be enrolled;\n  9. The myocardial enzyme profile is within the normal range (if the investigator comprehensively determines that the simple laboratory abnormality is not clinically significant, the patients is allowed to be enrolled); 12. Females of childbearing potential must have a negative urine or serum pregnancy test within 3 days prior to the first dose (Day 1 of Cycle 1). If a urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is requested. All female patients will be considered to be of childbearing potential unless they are naturally postmenopausal, underwent artificial menopause, or are surgically sterile (e.g., hysterectomy, bilateral adnexectomy).\n\n  13\\. If there is a risk of conception, Male or female patients of childbearing potential volunteer to use effective contraceptive methods (failure rate ≤ 1%) during the study and within 120 days after last administration of the study drug.\n\nExclusion Criteria:\n\n* Subjects must be excluded from this study when any one of the following criteria is met:\n\n  1. Presence of other malignancies in the past 5 years (except for basal cell carcinoma or squamous cell carcinoma of the skin and carcinoma in situ of the cervix, which were effectively controlled);\n  2. Currently participate in an interventional clinical study, or have been treated with another study drug or medical equipment within 4 weeks prior to the first dose;\n  3. Previous use of anti (PD-1), anti-PD-L1, anti-PD-L2 or CTLA-4 antibody or any other antibody acting on T cell co-stimulatory or checkpoint pathways (including but not limited to OX-40, CD137, etc.), anti-VEGF\u002FVEGFR-targeted drugs;\n  4. Having abnormal thyroid function with symptoms ongoing or requiring treatment at screening (only hypothyroidism that can be controlled by thyroid hormone replacement therapy can be included);\n  5. Received systemic therapy with anti-neuroendocrine tumor of proprietary Chinese medicines or immunomodulatory drugs (including thymosin, interferon and interleukin, except for local control of pleural effusion) within 2 weeks prior to the first dose;\n  6. Patients with any active autoimmune disorders requiring systematic treatment (e.g., palliative drugs, glucocorticoids, or immunosuppressants) or a history of autoimmune disease in the past 2 years. Alternative therapies (e.g. thyroxine, insulin, or physiologic glucocorticoids for adrenal or pituitary dysfunction) are not considered systemic;\n  7. Use of immunosuppressant within 7 days prior to the first dose, not including local glucocorticoid via nasal spray, inhalation or other routes or systemic glucocorticoid at physiological dose. Note: Physiological doses of glucocorticoids (≤10 mg\u002F day of prednisone or equivalent dose) are permitted;\n  8. Uncontrollable malignant hydrothorax, ascites or pericardial effusion (patients who do not need drainage effusion or who stop drainage for 3 days without significant increase in effusion can be included in the group);\n  9. Use of CYP3A potent or moderate inducers during the administration of concomitant medications or within 1 weeks or 5 half-lives (whichever is longer) prior to the first dose (Appendix 3);\n  10. Patients who currently have gastric and duodenal active ulcer, ulcerative colitis, or active bleeding in the unresected tumor, or serious gastrointestinal disorders, or other conditions that may cause haemorrhage of digestive tract or perforation;\n  11. Patients with evidence or history of obvious bleeding tendency within 2 months prior to the first dose. (bleeding within 2 months \\> 30 mL, hematemesis, black feces), hemoptysis (within 4 weeks \\> 5 mL of fresh blood);\n  12. Allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;\n  13. A history of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drugs (Sintilimab, IBI310, Surufatinib), or a prior history of severe allergy to any other monoclonal antibody.\n  14. Patients with multiple factors affecting oral medication (such as inability to swallow, post-gastrointestinal resection, chronic diarrhea and intestinal obstruction);\n  15. Toxicity from a previous anti-tumor treatment that does not return to Grade 0 or 1 (except for hair loss);\n  16. Human immunodeficiency virus (HIV) antibody positive;\n  17. Untreated active hepatitis B (defined as HBsAg positive with HBV-DNA copy number greater than the upper limit of the normal value in the laboratory department of the research center);\n\n      Note: Hepatitis B subjects who meet the following criteria can also be enrolled:\n\n  1\\) HBV viral load before initial administration \\\u003C 1000 copies\u002FmL (200 IU\u002Fml). Subjects should receive anti-HBV therapy to avoid virus reactivation 2) For patients with HBc (+), HBsAg (-), anti-HBS (-), and HBV viral load (-), prophylactic anti-HBV therapy is not required, but rigorous monitoring of virus reactivation is required;\n\n  18\\. Patients with known positive hepatitis C virus antibody (HCV Ab) and HCV RNA \\> 1 × 103 copies\u002FmL;\n\n  19\\. Vaccination of any live or attenuated live vaccine within 4 weeks prior to the first dose or during the study; Note: Acceptance of injectable inactivated virus vaccine against seasonal influenza is permitted within 30 days prior to first dose; Intranasally administered live attenuated flu vaccines are not allowed;\n\n  20\\. Pregnant (positive pregnancy test prior to administration) or lactating women;\n\n  21\\. Presence of any serious or uncontrollable systemic illness;\n\n  22\\. Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other condition that investigators suspect may prohibit use of the investigational product, affect interpretation of study results, or put the patient at high risk.","75 Years",{"count":170,"type":21},30,[25],"This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and safety of Sintilimab combined with IBI310 and Surufatinib for the treatment of high-grade advanced-neuroendocrine neoplasm",[30],"2025-03-11",{"date":176,"type":54},"2025-03-14",{"date":178,"type":54},"2022-07-12",{"date":180,"type":21},"2025-09",{"name":182,"class":129},"Peking University",2,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":130},"100581806","phase-2-absorbed-tumor-dose-in-peptide-receptor-radionuclide-therapy-with-long-acting-somatostatin-analogues---atsa-trial-100581806","NCT06855095","Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial","ATSA","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Able to provide spoken and written informed consent for the trial;\n* Histopathological confirmed neuroendocrine tumor;\n* Fulfill the clinical criteria for PRRT;\n* At least one soft tissue lesion \\> 2 cm;\n* Aimed administered activity of 7400 MBq;\n* ECOG score (performance status) 0-2.\n\nExclusion Criteria:\n\n* Not possible to discontinue LA-SSA for 4-6 weeks;\n* Use of short-acting SSAs;\n* Pregnancy and lactating female patients;\n* Inability to comply to the study procedures;\n* Factors that might affect the biodistribution (for example, indication for furosemide directly after PRRT infusion, limited fluid intake, any renal catheters, etc.).",{"count":192,"type":21},39,[25,194],"PHASE3","According to current guidelines, patients have to withhalt long-acting somatostatin analogues (LA-SSA) for 4-6 weeks prior to every 177Lutetium-DOTATATE administration. The primary objective of the study is to investigate the effect of LA-SSA on the absorbed dose in tumor lesions during PRRT.",[29,143,144,30],[198,199,200,201],"Peptide Receptor Radionuclide Therapy","PRRT","Lutetium","DOTATATE","2025-02-26",{"date":204,"type":54},"2025-03-03",{"date":206,"type":54},"2024-06-25",{"date":208,"type":21},"2027-03-01",{"name":210,"class":129},"The Netherlands Cancer Institute",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":130},"100576461","epigenomic-determinants-of-the-neuroendocrine-phenotype-as-biomarkers-for-neuroendocrine-neoplasms-100576461","NCT06785597","EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine Neoplasms","EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Noninvasive Diagnosis of Neuroendocrine Neoplasms","Inclusion Criteria:\n\n* Patient with histologically confirmed diagnosis of NEC\u002FMINEN amenable to surgery with radical intent\n* Patient with histologically confirmed diagnosis of NET amenable to surgery with radical intent\n* Patient with metastatic NET\u002FNEC, amenable to biopsy or surgery, including palliative intent\n* Patient histologically confirmed non-NEN histotype:\n\n  1. Colorectal carcinoma\n  2. Small intestine carcinoma\n  3. Gastric or oesophageal carcinoma\n  4. Pancreatic ductal adenocarcinoma\n  5. Metastasectomy from any non-NEN GI carcinoma\n\nExclusion Criteria:\n\n* Grading G1 and G2 \\\u003C=10% Ki67\n* Presence of concomitant neoplasm (within 3 years)\n* Concomitant major haematological alteration\n* Concomitant major organ dysfunction (e.g. G3\u002F4 liver or kidney failure)\n* Ongoing chemotherapy",{"count":219,"type":21},130,"For GEP mixed neuroendocrine (NE) non-neuroendocrine neoplasms (MiNENs) a key issue affecting prognosis is sometimes the difficulty in obtaining a timely diagnosis, as the NE component is often localized in deeper anatomical locations and\u002For becomes prevalent over time. The tissue material of biopsies may be not enough to define the NE component when this is particularly small and this could impact on therapeutic decision. Furthermore GEP NENs need to be characterized for potentially druggable biomarkers and liquid biopsy has clear advantage to the solid one to this aim. Here, we will exploit epigenetic differences characterizing NE tumors to build a DNA methylation-based liquid biopsy assay able to detect circulating tumor DNA of NE derivation, to enable the non-invasive diagnosis and monitoring of GEP-MiNENs.",[222,30],"Mixed Neuroendocrine-Non Neuroendocrine Neoplasm",[224,225,226,227],"global molecular profiling","neuroendocrine phenotype","biomarker","epigenomic determinant","2025-01-15",{"date":230,"type":54},"2025-01-21",{"date":232,"type":54},"2024-10-21",{"date":234,"type":21},"2026-10-21",{"name":236,"class":129},"European Institute of Oncology",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":5},"100506797","phase-2-a-study-of-pm8002-in-combination-with-chemotherapy-in-patients-with-nen-100506797","NCT05879055","A Study of PM8002 in Combination With Chemotherapy in Patients With NEN","A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Chemotherapy as Second Line Therapy in Unresectable Neuroendocrine Neoplasm","Inclusion Criteria:\n\n1. Signed informed consent form before any trial-related processes;\n2. Aged ≥ 18 years;\n3. Ki-67≥55% G3 NET and NEC were confirmed histologically or cytologically by pathological diagnosis in this study;\n4. Subjects failed first-line platinum-based chemotherapy;\n5. Adequate organ function;\n6. The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;\n7. Expected survival ≥ 12 weeks;\n8. Had at least one measurable tumor lesion according to RECIST v1.1;\n\nExclusion Criteria:\n\n1. History of severe allergic disease, severe drug allergy or have known allergy to any component of the study drugs;\n2. Evidence and history of severe bleeding tendency;\n3. History of severe cardiovascular diseases within 6 months;\n4. Subjects should provide formalin-fixed-paraffin-embedded (FFPE) tumor samples during the screening period (up to 24 months);\n5. Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;\n6. History of allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation;\n7. History of alcohol abuse, psychotropic substance abuse or drug abuse;\n8. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome;\n9. Pregnant or lactating women;\n10. Other conditions considered unsuitable for this study by the investigator.",{"count":140,"type":21},[25],"PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with FOLFIRI as second line treatment for neuroendocrine neoplasm (NEC and Ki-67≥55% G3 NET).",[30],[249,49,250],"Second line","G3 NET","2024-12-17",{"date":253,"type":54},"2024-12-19",{"date":255,"type":54},"2023-05-17",{"date":257,"type":21},"2028-01-01",{"name":259,"class":61},"Biotheus Inc.",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":273,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":130},"100432928","phase-2-dosimetry-based-prrt-versus-standard-dose-prrt-with-lu-177-dotatoc-in-nen-patients-100432928","NCT04917484","Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients","Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients- a Randomized Study; a Step Towards Tailored PRRT","DOBATOC","Inclusion Criteria:\n\n* 1\\. Male or female patients 18 years of age or more\n* 2\\. NEN confirmed by histology\n* 3\\. Clinical, PET\u002FCT or CT proven progression despite standard treatment with somatostatin analogues, targeted therapy (Everolimus, sunitinib), chemotherapy (STZ\u002F5-FU, temozolomide\u002Fcapecitabine) OR intolerable side effects caused by these standard treatment OR unmanageable carcinoid symptoms\n* 4\\. WHO\u002F ECOG Performance Status of 0-2\n* 5\\. Life expectancy more than 6 months\n* 6\\. Uptake higher than liver in primary tumor or metastases on Ga-DOTATOC PET\u002FCT (Krenning 3 or 4), if the scan is more than 3 months old at inclusion time, a new scan should be done.\n* 7\\. Adequate organ function as defined by:\n* Adequate kidney function: Patient glomerular filtration rate \\>30 ml\u002Fmin measured by Tc-DTPA clearance\n* Adequate bone marrow function:\n\n  * WBC ≥ 2.0 x 109\u002FL\n  * Platelets ≥ 100 x 109\u002FL\n  * Hb ≥ 6 mmol\u002Fl (≥9.67 g\u002FdL)\n* 8\\. Willingness and ability to comply with scheduled visits for SPECT\u002FCT scans, treatment plans, laboratory tests and other study procedures.\n\n  9\\. Written informed consent obtained prior to any screening procedures\n\nExclusion Criteria:\n\n* 1\\. Tumor amenable to surgery and\u002For radiofrequency ablation\n* 2\\. Patients who are unable to stay isolated for 24 hours\n* 3\\. Previous PRRT\n* 4\\. Female patients who are pregnant or lactating. Women who are of childbearing potential (defined as all women physiologically capable of becoming pregnant) have to practice an effective method of contraception\u002Fbirth control. Fertile female patients have to take a urinary pregnancy test, to ensure that they are not pregnant, before they can enter the study. After entering the study, they have to use effective contraception during the study period and 6 months after. Effective contraception methods include:\n* Use of oral, injected or implanted hormonal methods of contraception or\n* Placement of an intrauterine device (IUD) or intrauterine system (IUS)\n* Total abstinence or patient sterilization (male or female)\n* 5\\. Male patients are not allowed to conceive pregnancy for 6 months after last treatment cycle\n* 6\\. Known to be hypersensitive to any component of the Lu-177-DOTATOC\n* 7\\. Patients with meningioma",{"count":269,"type":21},100,[25],"In this study, we want to randomize patients with neuroendocrine neoplasms (NENs) who are eligible for peptide receptor radionuclide therapy (PRRT), to either standard PRRT consisting of 4 treatments with 7.4 GBq Lu-177-DOTATOC (standard arm) or 4 treatments with individualized doses of Lu-177-DOTATOC (dosimetry arm). In the dosimetry arm, the first dose depends on the patients' kidney function and thereafter the absorbed dose to the kidneys at the previous treatment. A max of 20GBq will be administered at the first treatment and 25GBq at treatment 2-4. We aim to reach an accumulated kidney dose of 24Gy.\n\nAfter the first treatment all patients will go through three SPECT\u002FCT scans 24 hours, 4 days, and 7 days, after treatment to calculate absorbed kidney dose. The patients in the standard dose treatment arm will have one SPECT\u002FCT scan after each of the last three treatments; all performed 24 hours after treatment, used to approximate the kidney dose assuming the clearance of the Lu-177 DOTATOC is the same after all treatments. The patients in the dosimetry based treatment arm will go through three SPECT\u002FCT scans after all four treatments for dosimetry calculation.\n\nBone marrow dosimetry is calculated after all treatments in the dosimetry based treatment arm and after the first treatment in the standard treatment arm. For bone marrow dosimetry, blood samples are drawn right before administration of Lu-177 DOTATOC (time 0) and 3 minutes, 45 minutes, 2 hours, 4 hours, 7-8 hours, 24 hours, 4 days, and 7 days after administration of Lu-177 DOTATOC.\n\nStandard blood samples are routinely drawn every 2nd week after every treatment in all included patients and analysed regarding liver, kidney and bone marrow function. Kidney clearance is evaluated with Tc-DTPA clearance at baseline.\n\nBlood and urinary samples will be collected at baseline and 3 months after the last treatment for kidney fibrosis analyses.\n\nAt baseline, blood and urine samples are collected for a biobank. All included patients fill in validated quality of life questionaires at all treatments.\n\nTo evaluate the effect of the treatment, all patients will be evaluated with standard CT scans prior to treatment and 3 and 9 months after the 4th treatment. Ga-68 DOTATOC PET will be performed at baseline and 6 and 12 months after the last treatment.",[30],[274,275],"Peptide receptor radionuclide therapy","Dosimetry","2024-12-06",{"date":278,"type":54},"2024-12-09",{"date":280,"type":54},"2020-02-01",{"date":282,"type":21},"2026-12",{"name":284,"class":129},"Tine Gregersen, MD",{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":291,"minAge":4,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":309},"100537321","protein-molecular-characteristics-and-prognosis-of-cervical-neuroendocrine-tumors-100537321","NCT06276309","Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors","Inclusion Criteria:\n\n1. Patients diagnosed with cervical neuroendocrine carcinoma by histopathology\n2. Clinical data were complete\n\nExclusion Criteria:\n\n1. Patients who are not being treated in our hospital\n2. Patients with lack of follow-up data, unable to obtain survival information\n3. Patients call to refuse to participate in this project\n4. The quality of paraffin specimens can not meet the requirements of proteome concentration determination","FEMALE",{"count":293,"type":21},300,"The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were collected, including age, preoperative biopsy pathology results, postoperative histopathological results, TCT results, and colposcopy biopsy pathology results. At the same time, paraffin tissue specimens (remaining specimens after pathological diagnosis) from 100 cases of cervical neuroendocrine tumors from multiple centers across the country were collected to establish a cervical neuroendocrine tumor data follow-up database. Protein concentration and omics analysis were performed on the data results, to evaluate the molecular characteristics and prognosis of cervical neuroendocrine tumor proteins, and to preliminarily explore its clinical application value.",[30,296,297,298,299],"China","Women","Cervical Cancer","Cervical Lesion","2024-09-12",{"date":302,"type":54},"2024-09-19",{"date":304,"type":54},"2024-02-01",{"date":306,"type":21},"2025-02-28",{"name":308,"class":129},"Fujian Maternity and Child Health Hospital",9,{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":316,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":355},"100556321","genetic-bases-of-neuroendocrine-neoplasms-in-mexican-patients-100556321","NCT06523582","Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients","Inclusion Criteria:\n\nAdult patients with a new or previous clinical diagnosis of any of the following conditions:\n\n* Isolated NENs with sporadic presentation, including bronchopulmonary NENs, gastrointestinal NENs, medullary thyroid carcinoma, pancreatic NENs, paragangliomas, pheochromocytomas, pituitary neuroendocrine tumors, and primary hyperparathyroidism.\n* Familial isolated NENs, including familial isolated pituitary adenoma, familial pheochromocytomas and paragangliomas, familial primary hyperparathyroidism, familial gastrointestinal stromal tumors and X-linked acrogigantism.\n* Clinical syndromes encompassing NENs, with familial or sporadic presentation, including Carney complex, Carney-Stratakis syndrome, Carney triad, Cowden syndrome, DICER1 syndrome, Li-Fraumeni syndrome, Lynch syndrome, multiple endocrine neoplasia type 1, multiple endocrine neoplasia type 2, multiple endocrine neoplasia type 4, neurofibromatosis type 1, Pacak-Zhuang syndrome, paraganglioma, pheochromocytoma and pituitary adenoma syndrome, tuberous sclerosis complex, Von Hippel Lindau syndrome.\n\nExclusion criteria:\n\n* Age \\\u003C18 years.\n* Refusal to give informed consent.",true,{"count":318,"type":21},750,"Neuroendocrine neoplasms (NENs) are a heterogeneous group of lesions derived from cells with the ability to produce hormones that may arise from multiple different organs. Their clinical behavior is quite variable, encompassing both benign lesions and aggressive tumors that invade surrounding and\u002For distant structures. NENs may also cause serious morbidity due to hormone oversecretion. NENs are among the most frequently inherited human tumors, presenting either isolated or as part of syndromes in which a single patient or family develops multiple tumors. There are also non-inherited changes in the genetic information of the tumor cells that are potential targets for treatment. Both inherited and non-inherited DNA defects can be identified using modern routine genetic tests which, unfortunately, are not widely available in Mexico.\n\nThis project seeks to uncover the genetic defects causing NENs in a large cohort of Mexican patients, using three different methods for genetic testing. Adult individuals with various types of NENs from two reference hospitals in Mexico City will be invited to participate. After completing informed consent, blood and, if possible, tissue samples will be obtained from all participants. Clinical details, laboratory results, imaging studies, and histopathological data at disease presentation will be retrieved.\n\nAn initial screening will be performed by analyzing changes in the sequence of multiple genes that have been associated with the occurrence of NENs. In cases with negative screening, a specific method to assess changes in the number of copies of the same genes will also be employed. Finally, sequences of all DNA regions encoding information required to make proteins will be obtained in selected cases. Analyses will be carried out in blood and, if available, also in tumor tissue samples from study participants. Screening of additional family members will be offered.\n\nThis project will accurately describe the repertoire of specific defects causing NENs in the study population, and will likely uncover and characterize novel genetic associations. The results will contribute for a better understanding of the alterations within and outside known driver genes that shape syndromic presentations, tumor behaviors, and inheritance patterns in individuals with NENs. These data will contribute to improve the information on the molecular bases of NENs, including alterations that can be used as therapeutic targets.",[30,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345],"Neuroendocrine Neoplasm of Gastrointestinal Tract","Neuroendocrine Neoplasm of Lung","Thymic Neuroendocrine Neoplasm","Neuroendocrine Tumor of Pancreas","Gastrointestinal Stromal Tumors","Medullary Thyroid Cancer","Paraganglioma","Pheochromocytoma","Primary Hyperparathyroidism","Pituitary Tumor","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Multiple Endocrine Neoplasia Type 4","Carney Complex","Carney Stratakis Dyad","Carney Triad","Cowden Syndrome","DICER1 Syndrome","Li-Fraumeni Syndrome","Lynch Syndrome","Von Hippel-Lindau Disease","Familial Isolated Pituitary Adenoma","X-Linked Acrogigantism","Neurofibromatosis 1","Tuberous Sclerosis","2024-07-22",{"date":348,"type":54},"2024-07-26",{"date":350,"type":54},"2022-08-03",{"date":352,"type":21},"2037-03-01",{"name":354,"class":129},"Universidad Nacional Autonoma de Mexico",3,{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":366,"conditions":367,"keywords":368,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":130},"100542481","definition-of-a-multiparametric-prognostic-and-predictive-system-of-classification-of-net-g3-patients-100542481","NCT06343428","Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients","Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients: an observAtional, Prospective Analysis of the Correlation Between Functional Imaging and Clinical Outcome (TAPIOCA)","TAPIOCA","Inclusion Criteria:\n\n* Histological diagnosis of well-differentiated neuroendocrine tumor G3 performed or reviewed by a NEN-dedicated pathologist. In case of \"late-NET G3\" (see Patients and Methods), a NEN-dedicated pathologist will perform a pathologic review of the previous NET G1\u002F2, too, unless a NEN-dedicated pathologist has already done and except for diagnoses performed in a NEN-referral Center.\n* Age \\> 18 years\n* Signed written informed consent\n* Available tumor tissue (formalin-fixed paraffin-embedded, FFPE) (preferably within 6 months). If the tumor contained in FFPE tissue block cannot be provided in total, sections from this block should be provided that are freshly cut. Preferably, 25 slides should be provided (minimum of 15 slides). If tumor tissue is not available, patients should be willing to undergone to a new biopsy.\n* late-NET G3 patients that will come to our Institute at the moment of NET G3 diagnosis will be enrolled only if they performed 68 Gallium-DOTATOC positron emission tomography (PET)\u002FCT and 18 fluorodeoxyglucose (FDG)-PET\u002FCT for the previous NET G1\u002F2. The previous functional imaging performed during the NET G1\u002F2 history shall be available for the review by our specialist in nuclear medicine.\n\nExclusion Criteria:\n\n* Diagnosis of well-differentiated NET G1\u002F2 or poorly-differentiated NEC\n* Diagnosis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) in which a NET G3 as neuroendocrine component\n* Cytological diagnosis of NET G3 or not availability of tumor tissue for pathological analysis\n* Concurrent neoplastic disease (e.g. advanced breast or prostatic cancer in hormonal treatment, hematologic diseases)",{"count":365,"type":21},20,"The 2017 World Health Organization (WHO) introduced a new category of high-grade, well-differentiated neuroendocrine neoplasms (NENs) that called neuroendocrine tumors (NETs) G3 in pancreatic NENs classification and, then, in 2019, for all gastro-entero-pancreatic (GEP) tract NENs.\n\nThe new classification made it possible to separate NETs G3 from high-grade, poorly-differentiated, NENs that are called neuroendocrine carcinomas (NECs).\n\nHowever, in clinical practice, we observed that several clinical, pathological and radiological differences are arising among NET G3 patients, suggesting that a multiparametric definition of NET G3 is needed.",[30],[369,370,371],"High-grade neuroendocrine neoplasm","prognostic factor","predictive factor","2024-05-03",{"date":374,"type":54},"2024-05-06",{"date":376,"type":54},"2021-07-19",{"date":378,"type":21},"2026-07-19",{"name":236,"class":129},{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":388,"enrollmentInfo":389,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":130},"100542045","young-adults-with-gastro-intestinal-gi-and-neuroendocrine-cancers-100542045","NCT06337760","YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.","YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs (YOUNGSTER).","YOUNGSTER","Inclusion Criteria:\n\n* Age at diagnosis from18 to 39 years of age\n* Carcinoma (without limitations for histologic subtypes) from any primary sites: esophagus, stomach, pancreas, biliary tract, liver, small bowel, colon, rectum, anus and cancer of unknown origin\n* Neuroendocrine neoplasm (NEN) from Gastroenteropancreatic GEP or lung\u002Fthymus origin\n* Tumors at any stage at the first visit\n* Tumors of any grade\n* Histological diagnosis obtained within two years from the time of enrollment or willingness to undergo bioptic procedure for diagnosis\n\nExclusion Criteria:\n\n* Age at diagnosis \\> 39 years old","39 Years",{"count":390,"type":21},90,"The objective of the study is to create a common and unique platform for the acquisition of biological samples and, subsequently, the possible identification of predictive and prognostic biomarkers for young adults with gastrointestinal and neuroendocrine cancers.The definition \"adolescent and young adults (AYA)\" covers a broad group of patients ranging from the upper limit of the paediatric competence to the youngest patients usually considered and treated as adults. However, a well-defined and universally accepted age range is still not established. Young adults with cancer have distinct epidemiological, biological, and clinical characteristics, as well as special medical and psychosocial needs that are often unmet. In consideration of their poor representation in clinical studies, as well as the rarer, albeit increasing, frequency at an epidemiological level, knowledge of the risk factors associated with cancers in young adults is very poor. It is therefore of fundamental importance to focus attention on this specific cohort of patients, in order to describe in ever more detail any specific biomolecular aspects, and make full use of the pharmacological resources currently available.",[30,393],"Adenocarcinoma",[395,396,397,398,399],"young adult","Gastro-intestinal cancer","Neuroendocrine cancer","molecular analysis","prognostic biomarker","2024-03-22",{"date":402,"type":54},"2024-03-29",{"date":404,"type":54},"2023-03-10",{"date":406,"type":21},"2027-06-30",{"name":236,"class":129}]